EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH ( COMMODORE 3): A multicenter, Phase 3, single‐arm study

Hui Liu, Linghui Xia, Jianyu Weng, Fengkui Zhang, Chuan He, Sujun Gao, Jinsong Jia iD, Alice C Chang, Pontus Lundberg, Jane Shi, Camelia S Sima, Alexandre Sostelly und 4 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26998 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Hui Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Phase 3 single‐arm COMMODORE 3 study ( ClinicalTrials.gov , NCT04654468) evaluated efficacy and safety of crovalimab (novel C5 inhibitor) in complement inhibitor‐naive patients with paroxysmal nocturnal hemoglobinuria (PNH). COMMODORE 3 enrolled patients from five China centers. Eligible complement inhibitor‐naive patients with PNH were ≥12 years old, had lactate dehydrogenase (LDH) ≥2 × upper limit of normal (ULN), and had ≥4 transfusions of packed red blood cells within the prior 12 months. Patients received crovalimab loading doses (one intravenous, four subcutaneous) and subsequent every‐4‐weeks subcutaneous maintenance doses per weight‐based tiered‐dosing schedule. Co‐primary efficacy endpoints were mean proportion of patients with hemolysis control (LDH ≤1.5 × ULN) from Week (W)5 through W25 and difference in proportion of patients with transfusion avoidance from baseline through W25 versus within 24 weeks of prescreening in patients who had ≥1 crovalimab dose and ≥1 central LDH assessment after first dose. Between March 17 and August 24, 2021, 51 patients (15–58 years old) were enrolled; all received treatment. At primary analysis, both co‐primary efficacy endpoints were met. Estimated mean proportion of patients with hemolysis control was 78.7% (95% CI: 67.8–86.6). Difference between proportion of patients with transfusion avoidance from baseline through W25 (51.0%; n = 26) versus within 24 weeks of prescreening (0%) was statistically significant ( p < .0001). No adverse events led to treatment discontinuation. One treatment‐unrelated death (subdural hematoma following a fall) occurred. In conclusion, crovalimab, with every‐4‐weeks subcutaneous dosing is efficacious and well tolerated in complement inhibitor‐naive patients with PNH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansChildAdolescentYoung AdultAdultMiddle AgedAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsHemolysisAntibodies, MonoclonalComplement C5

Substanzen

Antibodies, Monoclonal, HumanizedComplement Inactivating AgentsAntibodies, MonoclonalComplement C5

Autor:innen und Institutionen

  • Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
  • Division of Bone Marrow Transplantation, Institute of Hematology, Wuhan Union Hospital, Wuhan, People's Republic of China.
  • Department of Hematology, Guangdong Provincial People's Hospital, Guangdong, People's Republic of China.
  • Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Tianjin, People's Republic of China.
  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
  • Department of Hematology, The First Hospital of Jilin University, Changchun, People's Republic of China.

ORCID-Profile: Jinsong Jia, Rong Fu

Zitieren

APA

Liu, H., Xia, L., Weng, J., Zhang, F., He, C., Gao, S., Jia, J., Chang, A. C., Lundberg, P., Shi, J., Sima, C. S., Sostelly, A., Sreckovic, S., Xiao, Z., Zhang, Z., & Fu, R. (2023). Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH ( COMMODORE 3): A multicenter, Phase 3, single‐arm study. American Journal of Hematology. https://doi.org/10.1002/ajh.26998

Vancouver

Liu H, Xia L, Weng J, Zhang F, He C, Gao S, et al. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH ( COMMODORE 3): A multicenter, Phase 3, single‐arm study. American Journal of Hematology. 2023. doi:10.1002/ajh.26998

BibTeX
@article{Liu2023,
  author = {Liu, Hui and Xia, Linghui and Weng, Jianyu and Zhang, Fengkui and He, Chuan and Gao, Sujun and Jia, Jinsong and Chang, Alice C and Lundberg, Pontus and Shi, Jane and Sima, Camelia S and Sostelly, Alexandre and Sreckovic, Sasha and Xiao, Zhenyu and Zhang, Zilu and Fu, Rong},
  title = {Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH ( COMMODORE 3): A multicenter, Phase 3, single‐arm study},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26998}
}
Kostenlos starten →